medigraphic.com
ISSN 1561-3070 (Electronic)

2012, Number 2

<< Back Next >>

Rev Cub Oftal 2012; 25 (2)

Use of Bevacizumab in corneal neovascularization

Cárdenas DT, Torres OR, Corcho AY, Cruz ID, Capote CA, Benítez MMC

Language: Spanish
References: 12
Page:
PDF size: 119.31 Kb.


ABSTRACT

Neovascularization of the cornea is a cause of loss of transparency of the same and is also a risk factor for secondary rejection corneal transplants. Bevacizumab is a humanized monoclonal antibody that selectively blocks the formation of the VEGF cascade and, with this, decreases the formation of blood vessels. Three cases with corneal neovascularization from different causes were presented, which were given three doses of 2.5 mg subconjunctival bevacizumab once a month. A partial regression of corneal neovascularization was observed in the treated eyes, being more visible in the patient with a history of corneal burn.


REFERENCES

  1. Jareño M, Castillo A, Capote A. Angiogénesis corneal. En: Río M, Capote A, Hernández R, Eguía F, Padilla CM. Oftalmología. Criterios y tendencias actuales. La Habana: Editorial Ciencias Médicas; 2010. p. 80-5.

  2. Niederkorn JY, Kaplan HJ. Immune Response and the Eye. Chem Immunol Allergy. 2007;92(1):50-7.

  3. Cursiefen C, Kruse F. New aspects of angiogenesis in the cornea. In: Krieglstein GK, Weinreb RN. Corneal and External Eye Disease. Germany: Springer Berlin Heidelberg; 2006. p. 82-99.

  4. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (An American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104:264-302.

  5. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res. 2001;9(3):507-21.

  6. Zúñiga J, Maass JC, Amagada C. Efecto del factor de crecimiento del endotelio vascular (VEGF) sobre perforaciones timpánicas en ratas Long-Evans. Rev Otorrinolaringol Cir Cabeza Cuello. 2001;67(1):7-12.

  7. García E, Macías Y, Rodríguez A. Uso de bevacizumab subconjuntival para el manejo de la neovascularización corneal. Rev Mex Oftalmol. 2010;84(1):5-9

  8. Epstein RJ, Stulting RD, Hendricks RL, Harris DM. Corneal Neovascularization. Pathogenesis and inhibition. Cornea. 1987;6(4):250-57.

  9. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2007;245(10):1577-9.

  10. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for Vascular Endothelial Growth Factor in Wound- and Inflammation- Related Corneal Neovascularization. Invest Ophthal Vis Sci. 1998;39(1):18-22.

  11. Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A. Subconjunctival Bevacizumab Injection for Corneal Neovascularization. Cornea. 2008;27(2):142-7.

  12. Kim SW, Ha BJ, Kim EK, Tchah H, Kim T. The Effect of Topical Bevacizumab on Corneal Neovascularization. Ophthalmology. 2008;115(6):33-8.




2020     |     www.medigraphic.com